search
Back to results

Self Sampling for Rapid Turnaround Testing in the Emergency Department

Primary Purpose

Chlamydia Trachomatis, Neisseria Gonorrhoeae

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
vaginal self sampling
provider-performed endocervical sampling
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Chlamydia Trachomatis focused on measuring Chlamydia, Gonorrhea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult female emergency department patient felt by the provider to require gonorrhea/chlamydia endocervical testing

Exclusion Criteria:

  • Non-English speakers with the exception of Spanish speakers (once a Spanish-language informed consent document is approved by the Community Medical Center Institutional Review Board)
  • Prisoner
  • Age <18 years old
  • Active psychiatric condition felt to preclude the ability to give informed consent
  • Treated for gonorrhea/chlamydia within previous four weeks

Sites / Locations

  • Community Regional Trauma and Burn Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Vaginal self-sampling and provider performed endocervical sampling

Arm Description

Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.

Outcomes

Primary Outcome Measures

Noninferiority of vaginal self-sampling compared to provider performed endocervical sampling for gonorrhea/chlamydia diagnosis
In order for vaginal self-sampling to be considered clinically noninferior to the standard provider-performed endocervical sampling method of collection, we established a minimum sensitivity of 90%. This was based on previous research showing Sexually Transmitted Infection (STI) clinicians' top priority for a point of care STI test is a minimum sensitivity of 90%. In addition, a previous ED study examining urine gonorrhea/chlamydia diagnosis using the same point of care test as this study also used a minimum sensitivity of 90%. (9) Thus, our primary outcome measure was examining for the noninferiority of VSS sensitivity for gonorrhea/chlamydia, with noninferiority being demonstrated if the sensitivity is >=90%.

Secondary Outcome Measures

Predictive value
Vaginal self-sampling specificity, positive predictive value, negative productive value for gonorrhea/chlamydia (measured by individual patient)
Predictive value-Gonorrhea
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for gonorrhea
Predictive value-Chlamydia
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for chlamydia
Demographics
Concordance of vaginal self-sampling to provider-performed endocervical sampling
Percentage
Acceptance rate vaginal self-sample
Rate-Worried
Rate of patients worried about doing vaginal self-sampling and correctly
Rate-Prefer
Rate of patients that prefer vaginal self-sample to provider-performed endocervical sampling
Numeric
Number of patients that refused vaginal self-sampling
Descriptive
Description of reasons for refusal of vaginal self-sampling

Full Information

First Posted
September 17, 2018
Last Updated
July 29, 2021
Sponsor
University of California, San Francisco
Collaborators
Central California Faculty Medical Group
search

1. Study Identification

Unique Protocol Identification Number
NCT03676816
Brief Title
Self Sampling for Rapid Turnaround Testing in the Emergency Department
Official Title
Vaginal Self-sampling for Rapid Turnaround Gonorrhea/Chlamydia Testing in the Emergency Department
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
September 17, 2018 (Actual)
Primary Completion Date
June 9, 2020 (Actual)
Study Completion Date
June 9, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Central California Faculty Medical Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Consenting adult female patient felt by the provider to require gonorrhea/chlamydia endocervical testing will be asked to provide an additional self sample specimen. The specimen will be sent to the laboratory using conventional diagnostic test for gonorrhea/chlamydia.
Detailed Description
Study protocol: Initial emergency department history and physical examination (standard procedure). a. Provider identifies patient who is felt to require gonorrhea/chlamydia testing. i. Provider will contact study staff to consent patient. b. Study staff identifies patient who is felt by provider to require gonorrhea/chlamydia testing. i. Study staff will ask provider if they could move forward with consenting patient. c. Provider who is study staff identifies patient who is felt to require gonorrhea/chlamydia testing. Study staff will attempt to consent patient. If inclusion criteria are met, and there are no exclusion criteria, written informed consent is obtained. If the patient changes her mind and refuses consent at this point, a notation is written on the front of the research packet, and it is turned in with a refusal notice on the packet. If patient refuses to participate in the self-sampling portion of the study, we will ask patients if they would like to fill out the first half of the patient survey that will contain no personal identification information besides their initials. If patient agrees to participate in the self-sampling, the patient is asked to fill out both page one and page two of the survey after consent is obtained. An attempt is made to write down at least two contact telephone numbers for patients who have given informed consent on page 2 of the patient survey. The patient obtains vaginal self-sample in the restroom/exam room. A preprinted single-use instruction sheet is given to patient detailing sample collection. Vaginal self-sampling collection container has preprinted instructions/requisition and a preprinted label on the Cepheid sample tube to the lab denoting this as research sample. Paper requisition form is also included with the sample which helps with documentation and assigning this sample to be billed to the research study and not to the patient. The patient returns the collection container after obtaining the sample to study staff that consented the patient. The collection container will be sent to the lab via pneumatic tube station. Vaginal self-sampling result is documented in Epic with designation showing differentiation from provider-performed endocervical sampling. Provider-performed endocervical sampling is performed once the patient is assigned a provider and given a private area to conduct a provider-performed endocervical sampling (standard procedure). a. The collection container is sent to the lab, and the final result is noted in the medical record as per standard practice (standard procedure). Retrospective chart review is performed three days after patient consented in order to obtain provider-performed endocervical sampling results. Patient will be contacted only if there is a false-negative. A positive with either the self-sample or provider collected sample is considered positive, and patient will not be called back about that

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chlamydia Trachomatis, Neisseria Gonorrhoeae
Keywords
Chlamydia, Gonorrhea

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
533 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vaginal self-sampling and provider performed endocervical sampling
Arm Type
Experimental
Arm Description
Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
Intervention Type
Procedure
Intervention Name(s)
vaginal self sampling
Other Intervention Name(s)
Cepheid, SWAB/A-50
Intervention Description
This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
Intervention Type
Procedure
Intervention Name(s)
provider-performed endocervical sampling
Intervention Description
provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
Primary Outcome Measure Information:
Title
Noninferiority of vaginal self-sampling compared to provider performed endocervical sampling for gonorrhea/chlamydia diagnosis
Description
In order for vaginal self-sampling to be considered clinically noninferior to the standard provider-performed endocervical sampling method of collection, we established a minimum sensitivity of 90%. This was based on previous research showing Sexually Transmitted Infection (STI) clinicians' top priority for a point of care STI test is a minimum sensitivity of 90%. In addition, a previous ED study examining urine gonorrhea/chlamydia diagnosis using the same point of care test as this study also used a minimum sensitivity of 90%. (9) Thus, our primary outcome measure was examining for the noninferiority of VSS sensitivity for gonorrhea/chlamydia, with noninferiority being demonstrated if the sensitivity is >=90%.
Time Frame
2-3 days
Secondary Outcome Measure Information:
Title
Predictive value
Description
Vaginal self-sampling specificity, positive predictive value, negative productive value for gonorrhea/chlamydia (measured by individual patient)
Time Frame
2-3 days
Title
Predictive value-Gonorrhea
Description
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for gonorrhea
Time Frame
2-3 days
Title
Predictive value-Chlamydia
Description
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for chlamydia
Time Frame
2-3 days
Title
Demographics
Description
Concordance of vaginal self-sampling to provider-performed endocervical sampling
Time Frame
2-3 days
Title
Percentage
Description
Acceptance rate vaginal self-sample
Time Frame
2-3 days
Title
Rate-Worried
Description
Rate of patients worried about doing vaginal self-sampling and correctly
Time Frame
2-3 days
Title
Rate-Prefer
Description
Rate of patients that prefer vaginal self-sample to provider-performed endocervical sampling
Time Frame
2-3 days
Title
Numeric
Description
Number of patients that refused vaginal self-sampling
Time Frame
2-3 days
Title
Descriptive
Description
Description of reasons for refusal of vaginal self-sampling
Time Frame
2-3 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult female emergency department patient felt by the provider to require gonorrhea/chlamydia endocervical testing Exclusion Criteria: Non-English speakers with the exception of Spanish speakers (once a Spanish-language informed consent document is approved by the Community Medical Center Institutional Review Board) Prisoner Age <18 years old Active psychiatric condition felt to preclude the ability to give informed consent Treated for gonorrhea/chlamydia within previous four weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian Chinnock, MD
Organizational Affiliation
UCSF - Fresno
Official's Role
Principal Investigator
Facility Information:
Facility Name
Community Regional Trauma and Burn Center
City
Fresno
State/Province
California
ZIP/Postal Code
93721
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
12865101
Citation
Levitt MA, Johnson S, Engelstad L, Montana R, Stewart S. Clinical management of chlamydia and gonorrhea infection in a county teaching emergency department--concerns in overtreatment, undertreatment, and follow-up treatment success. J Emerg Med. 2003 Jul;25(1):7-11. doi: 10.1016/s0736-4679(03)00131-8.
Results Reference
background
PubMed Identifier
23471445
Citation
Huppert JS, Taylor RG, St Cyr S, Hesse EA, Reed JL. Point-of-care testing improves accuracy of STI care in an emergency department. Sex Transm Infect. 2013 Sep;89(6):489-94. doi: 10.1136/sextrans-2012-050994. Epub 2013 Mar 7.
Results Reference
background
PubMed Identifier
26119905
Citation
Holley CE, Van Pham T, Mezzadra HM, Willis GC, Witting MD. Overtreatment of gonorrhea and chlamydial infections in 2 inner-city emergency departments. Am J Emerg Med. 2015 Sep;33(9):1265-8. doi: 10.1016/j.ajem.2015.06.009. Epub 2015 Jun 12.
Results Reference
background
PubMed Identifier
29067905
Citation
Terkelsen D, Tolstrup J, Johnsen CH, Lund O, Larsen HK, Worning P, Unemo M, Westh H. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Euro Surveill. 2017 Oct;22(42):17-00659. doi: 10.2807/1560-7917.ES.2017.22.42.17-00659.
Results Reference
background
PubMed Identifier
28549097
Citation
Katz AR, Komeya AY, Kirkcaldy RD, Whelen AC, Soge OO, Papp JR, Kersh EN, Wasserman GM, O'Connor NP, O'Brien PS, Sato DT, Maningas EV, Kunimoto GY, Tomas JE. Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016. Clin Infect Dis. 2017 Sep 15;65(6):918-923. doi: 10.1093/cid/cix485.
Results Reference
background
PubMed Identifier
28100761
Citation
Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect. 2017 Feb;93(1):56-61. doi: 10.1136/sextrans-2016-052609. Epub 2016 Oct 19.
Results Reference
background

Learn more about this trial

Self Sampling for Rapid Turnaround Testing in the Emergency Department

We'll reach out to this number within 24 hrs